デフォルト表紙
市場調査レポート
商品コード
1757971

アンデルセン・タウィル症候群(ATS)の世界市場

Andersen-Tawil Syndrome (ATS)


出版日
ページ情報
英文 276 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
アンデルセン・タウィル症候群(ATS)の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 276 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アンデルセン・タウィル症候群(ATS)の世界市場は2030年までに310万米ドルに達する見込み

2024年に220万米ドルと推定されるアンデルセン・タウィル症候群(ATS)の世界市場は、2024~2030年の分析期間においてCAGR 5.7%で成長し、2030年には310万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである1型疾患は、CAGR 4.5%を記録し、分析期間終了時には180万米ドルに達すると予測されます。2型疾患セグメントの成長率は、分析期間中CAGR 7.4%と推定されます。

米国市場は59万9,500米ドルと推定、中国はCAGR 8.7%で成長すると予測

米国のアンデルセン・タウィル症候群(ATS)市場は2024年に59万9,500米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年にかけてCAGR 8.7%で推移し、2030年には61万900米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.8%と5.5%と予測されています。欧州では、ドイツがCAGR 3.7%で成長すると予測されています。

世界のアンデルセン・タウィル症候群(ATS)市場- 主要動向と促進要因まとめ

アンデルセン・タウィル症候群が希少疾患コミュニティで注目を集める理由とは?

アンデルセン・タウィル症候群は極めて稀な疾患であるが、その複雑な症状と診断上の課題から、研究者、臨床医、患者支援団体から関心が高まっています。常染色体優性遺伝であるこの疾患は、周期性麻痺、特徴的な顔貌と骨格、心不整脈の三徴候によって特徴づけられるが、早期発見と効果的な管理のための大きな障害となっています。従来は、より一般的な疾患と症状が重複するため、診断が遅れたり、誤分類されることが多かったが、遺伝子検査や臨床意識の進歩により、ATSが認識されるようになってきています。より洗練された表現型解析技術と次世代シーケンサーの出現により診断精度が向上し、ATSと他の神経筋疾患や心疾患との鑑別が容易になりました。このことが、世界中で確認された症例の着実な増加に寄与し、研究とケアへのより集中的なアプローチを促しています。

さらに、希少疾患の早期診断と的を絞った治療を推進する希少疾患コミュニティの努力は、ATSの認知度に直接的な影響を与えています。患者支援団体は、教育的リソースを普及させ、早期介入戦略を支援し、罹患家族を専門ケアセンターにつなぐ上で極めて重要な役割を果たしています。公衆衛生機関も希少疾患登録への投資を増やしており、ATSのような疾患に関する包括的なデータセットの構築に役立っています。これらの登録は疫学的な理解を深めるだけでなく、遺伝子型と表現型の相関や長期的な疾患の進行に関する調査にも役立っています。現在では、心電図異常や形態異常とともに原因不明の筋力低下エピソードを呈する患者に対して、ATSを考慮するよう臨床医に推奨されることが多くなっています。その結果、ATSは医学的な謎から、神経筋学や循環器学の領域で十分に認知された症候群へと移行しつつあり、より的を絞った治療や診断のための解決策が求められています。

診断ツールと遺伝学的知見は、ATS管理戦略をどのように変革しているか?

分子遺伝学とプレシジョン・メディシンの統合が進んでいることもあり、情勢は急速に変化しています。ATSの中心にはKCNJ2遺伝子の変異があり、この遺伝子は筋収縮と心リズムの調節に関与するカリウムイオンチャネルをコードしています。遺伝子検査によってこの変異を同定することは、ATS診断の要となっており、臨床医は疑いのある症例を高い確実性で確認することができます。遺伝子検査は現在、より広く利用できるようになり、価格も手頃になったため、家族性のパターンを検出し、無症状の親族に対するリスク評価を導くのに役立っています。このことは、本疾患に関連する不整脈が生命を脅かす可能性があることを考慮すると、早期の心臓モニタリングと介入にとって極めて重要です。

診断にとどまらず、遺伝学的知見は治療アプローチにも影響を及ぼしています。ATSの根底にある分子メカニズムを理解することで、研究者はイオンチャネル機能を調節する標的療法を模索しています。現在のところ治療法は存在しないが、生活習慣の改善、薬理学的介入、心臓監視などを組み合わせた個別化治療計画が一般的になりつつあります。例えば、周期性麻痺の治療にはカリウムの補給が行われ、重篤な心臓症状を呈する患者には抗不整脈薬や植え込み型除細動器(ICD)が処方されます。ウェアラブルヘルス技術の進歩により、心臓の活動や筋肉のパフォーマンスをリアルタイムでモニタリングできるようになり、管理はさらに改善されています。これらのツールは、重篤な事象に対する早期警告を提供するだけでなく、長期的なデータ収集も容易にし、研究や個別化ケアに貢献しています。このような遺伝学、診断学、テクノロジーの融合は、ATSのアプローチ方法に革命をもたらし、管理を反応的なものではなく予防的なものにしています。

ATS治療薬の開発にはどのような課題と機会があるのか?

アンデルセン・タウィル症候群に対する効果的な治療薬の開発には、障害と新たな可能性が混在しています。最も大きな課題のひとつは、患者数が少なく分散しているため、大規模臨床試験を実施し、統計的に有意なデータを収集することが困難であることです。症状の種類、重症度、頻度が多岐にわたるというこの疾患の異質性は、標準化された治療プロトコルの作成をさらに複雑にしています。さらに、ATSの症状は他の疾患と重複しているため、診断が遅れることが多く、早期治療介入の窓口が狭まっています。商業的なインセンティブが限られているため、大手製薬企業はATSに特化した薬剤開発に多額の投資をすることができず、他の疾患を対象とした薬剤の適応外使用に依存せざるを得ないのが現状です。

このような障壁にもかかわらず、希少疾患治療薬のエコシステムの拡大により、楽観的な見方が広がっています。薬剤再利用の進歩により、研究者は既存のイオンチャネル調節薬や抗不整脈薬のATS患者における有効性を評価できるようになっています。この戦略により、開発期間とコストが大幅に短縮され、治療薬を市場に投入することがより現実的になっています。これと並行して、患者登録と国際的な共同研究は、データとリソースの統合を助け、より統一された研究戦線を形成しています。規制当局もまた、希少疾病用医薬品の指定や早期承認プロセスといった道を提供し、この分野における技術革新にインセンティブを与えています。CRISPRに基づく遺伝子編集やRNA標的治療などの新技術は、まだ初期段階にあるもの、根本的な遺伝子変異を長期的に修正する可能性を秘めています。これらの開発は、パラダイムシフトを示唆しており、課題にもかかわらず、ATS治療の状況は、科学、政策、患者の支持に後押しされ、有意義な変化の尖端にあることを示唆しています。

アンデルセン・タウィル症候群市場の成長を促す要因は何か?

アンデルセン・タウィル症候群市場の成長は、診断法の進歩、認知度の向上、治療法の探求の拡大、医療政策の支持などに関連するいくつかの重要な要因によって牽引されています。その最たるものが遺伝子検査の役割であり、ATS症例の同定を劇的に改善しました。シーケンシング技術がより利用しやすくなり、標準的な診断プロトコールに組み込まれるにつれて、より多くの患者が無症候期であっても正しく診断されるようになっています。このことは、この疾患の全体的な診断有病率を増加させるだけでなく、より多くの患者をヘルスケアシステムに取り込むことになり、診察、モニタリングツール、治療選択肢に対する需要を刺激します。同時に、神経科医、心臓専門医、遺伝専門医を結集した集学的治療アプローチの台頭は、ATS患者に提供できる治療の質を高め、診断薬、心臓インプラント、希少疾患治療薬などの関連市場の成長をさらに後押ししています。

希少疾患に対する官民の関心も大きな推進力となっています。各国政府は、資金援助プログラム、研究助成金、規制上の優遇措置へのアクセスなど、希少疾病治療を支援するイニシアチブを導入しています。こうした支援は、バイオテクノロジー新興企業や中堅製薬企業のATS分野への参入を促し、新薬候補の開発や既存治療法の適応を促しています。一方、世界の患者アドボカシーは、患者の声が研究の優先順位、臨床試験デザイン、資金配分に影響を与えるようにすることで、市場を再構築しています。遠隔心電図モニターや患者データアプリなどのデジタルヘルスツールの統合も、継続的な症状追跡、早期介入、実世界でのエビデンス収集を可能にすることで市場機会を拡大しています。さらに、プライマリ・ケア提供者を対象とした教育的取り組みにより、ATS症状の早期認知が進み、迅速な紹介と患者の転帰改善につながります。このように相互にリンクする力は、ATS市場の着実な成長を促すだけでなく、希少疾患ケアにおける患者中心の長期的な技術革新の基盤となっています。

セグメント

疾患タイプ(1型疾患、2型疾患)、流通チャネル(病院薬局、小売薬局、オンライン流通チャネル)

調査対象企業の例(全42社)

  • AbbVie Inc.
  • Advanz Pharma
  • Alembic Pharmaceuticals
  • Alexion Pharmaceuticals
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AIインテグレーション

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入(完成品とOEM)に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価(COGS)の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36163

Global Andersen-Tawil Syndrome (ATS) Market to Reach US$3.1 Million by 2030

The global market for Andersen-Tawil Syndrome (ATS) estimated at US$2.2 Million in the year 2024, is expected to reach US$3.1 Million by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Type 1 Disease, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$1.8 Million by the end of the analysis period. Growth in the Type 2 Disease segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$599.5 Thousand While China is Forecast to Grow at 8.7% CAGR

The Andersen-Tawil Syndrome (ATS) market in the U.S. is estimated at US$599.5 Thousand in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$610.9 Thousand by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Andersen-Tawil Syndrome (ATS) Market - Key Trends & Drivers Summarized

Why Is Andersen-Tawil Syndrome Garnering Increased Attention in the Rare Disease Community?

Andersen-Tawil Syndrome (ATS), though extremely rare, is drawing growing interest from researchers, clinicians, and patient advocacy groups due to its complex symptomology and diagnostic challenges. This autosomal dominant disorder-characterized by a triad of periodic paralysis, distinctive facial and skeletal features, and cardiac arrhythmias-presents significant hurdles for early detection and effective management. Traditionally underdiagnosed or misclassified due to overlapping symptoms with more common conditions, ATS is now increasingly being recognized thanks to advances in genetic testing and clinical awareness. The emergence of more refined phenotyping techniques and next-generation sequencing has improved diagnostic accuracy, making it easier to distinguish ATS from other neuromuscular or cardiac disorders. This has contributed to a steady rise in identified cases worldwide, prompting a more focused approach to research and care.

Furthermore, the rare disease community’s efforts to push for earlier diagnosis and targeted treatment for orphan diseases are having a direct impact on ATS awareness. Patient advocacy groups are playing a pivotal role in disseminating educational resources, supporting early intervention strategies, and connecting affected families with specialized care centers. Public health agencies, too, are investing more in rare disease registries, which are helping build comprehensive datasets on conditions like ATS. These registries not only improve epidemiological understanding but also guide research into genotype-phenotype correlations and long-term disease progression. Clinicians are now more frequently encouraged to consider ATS in patients presenting with unexplained episodes of muscle weakness alongside ECG abnormalities or dysmorphic features. As a result, ATS is transitioning from being a medical enigma to a well-recognized syndrome within the neuromuscular and cardiology communities, setting the stage for more targeted therapeutic and diagnostic solutions.

How Are Diagnostic Tools and Genetic Insights Transforming ATS Management Strategies?

The landscape for diagnosing and managing Andersen-Tawil Syndrome is evolving rapidly, thanks in large part to the growing integration of molecular genetics and precision medicine. At the heart of ATS lies a mutation in the KCNJ2 gene, which encodes a potassium ion channel involved in regulating both muscle contraction and cardiac rhythm. Identifying this mutation through genetic testing has become a cornerstone of ATS diagnosis, enabling clinicians to confirm suspected cases with a high degree of certainty. Genetic testing is now more widely available and affordable, helping detect familial patterns and guiding risk assessment for asymptomatic relatives. This has led to an increase in pre-symptomatic diagnoses, which is critical for early cardiac monitoring and intervention, given the life-threatening potential of arrhythmias associated with the disorder.

Beyond diagnosis, genetic insights are also influencing treatment approaches. By understanding the molecular mechanisms underlying ATS, researchers are exploring targeted therapies that modulate ion channel function. Although no cure currently exists, individualized treatment plans are becoming more common, incorporating a mix of lifestyle modifications, pharmacological interventions, and cardiac surveillance. For example, potassium supplementation is used to manage periodic paralysis, while antiarrhythmic drugs and implantable cardioverter-defibrillators (ICDs) are prescribed in patients with severe cardiac manifestations. Advances in wearable health technology have further improved management, allowing real-time monitoring of cardiac activity and muscle performance. These tools not only provide early warnings for serious events but also facilitate long-term data collection, contributing to research and personalized care. This fusion of genetics, diagnostics, and technology is revolutionizing the way ATS is approached, making management more proactive rather than reactive.

What Challenges and Opportunities Exist in the Development of ATS Therapeutics?

Developing effective therapeutics for Andersen-Tawil Syndrome presents a unique mix of obstacles and emerging possibilities, largely due to the syndrome’s rarity and clinical variability. One of the foremost challenges lies in the small and dispersed patient population, which makes it difficult to conduct large-scale clinical trials and gather statistically significant data. The heterogeneous nature of the disease-where symptoms can range widely in type, severity, and frequency-further complicates the creation of standardized treatment protocols. Moreover, the overlap of ATS symptoms with other disorders often delays diagnosis, reducing the window for early therapeutic intervention. Limited commercial incentives have historically discouraged major pharmaceutical players from investing heavily in ATS-specific drug development, leading to a reliance on off-label use of drugs intended for other conditions.

Despite these barriers, there is a growing wave of optimism driven by the expanding rare disease drug ecosystem. Advances in drug repurposing are enabling researchers to evaluate existing ion channel modulators and antiarrhythmic agents for efficacy in ATS patients. This strategy significantly reduces development timelines and costs, making it more feasible to bring treatments to market. In parallel, patient registries and international collaborations are helping to consolidate data and resources, creating a more unified research front. Regulatory bodies are also providing pathways like orphan drug designations and accelerated approval processes to incentivize innovation in this space. Emerging technologies such as CRISPR-based gene editing and RNA-targeted therapies, while still in early stages, hold potential for long-term correction of the underlying genetic mutation. These developments signal a paradigm shift, suggesting that despite its challenges, the ATS therapeutic landscape is on the cusp of meaningful change, driven by science, policy, and patient advocacy.

Which Factors Are Driving Growth in the Andersen-Tawil Syndrome Market?

The growth in the Andersen-Tawil Syndrome market is driven by several critical factors linked to advances in diagnostics, increasing awareness, expanding therapeutic exploration, and supportive healthcare policy. At the forefront is the role of genetic testing, which has dramatically improved the identification of ATS cases. As sequencing technologies become more accessible and are integrated into standard diagnostic protocols, more patients are being correctly diagnosed, even during asymptomatic phases. This not only increases the overall diagnosed prevalence of the condition but also brings a larger patient population into the healthcare system, stimulating demand for medical consultations, monitoring tools, and therapeutic options. At the same time, the rise in multidisciplinary care approaches-bringing together neurologists, cardiologists, and geneticists-is elevating the quality of care available for ATS patients, further reinforcing the growth of associated markets such as diagnostics, cardiac implants, and rare disease therapeutics.

Public and private sector interest in rare diseases is another major driver. Governments are introducing initiatives to support orphan disease treatment, including funding programs, research grants, and access to regulatory incentives. This support has encouraged biotech startups and mid-sized pharmaceutical firms to enter the ATS space, developing novel drug candidates or adapting existing therapies. Meanwhile, global patient advocacy is reshaping the market by ensuring that patient voices influence research priorities, clinical trial design, and funding allocations. The integration of digital health tools-such as remote ECG monitors and patient data apps-is also expanding market opportunities by enabling ongoing symptom tracking, early intervention, and real-world evidence collection. Furthermore, educational efforts targeted at primary care providers are increasing early recognition of ATS symptoms, which leads to faster referrals and better patient outcomes. These interlinked forces are not only driving steady growth in the ATS market but are also setting the foundation for long-term, patient-centric innovation in rare disease care.

SCOPE OF STUDY:

The report analyzes the Andersen-Tawil Syndrome (ATS) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Type 1 Disease, Type 2 Disease); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie Inc.
  • Advanz Pharma
  • Alembic Pharmaceuticals
  • Alexion Pharmaceuticals
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Andersen-Tawil Syndrome (ATS) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Diagnostic Accuracy Spur Early Identification and Clinical Management of Andersen-Tawil Syndrome (ATS)
    • Advancements in Genetic Testing Technologies Strengthen the Business Case for Precision Diagnosis in Rare Channelopathies
    • Here's How Increased Inclusion of ATS in Neuromuscular Disease Panels Expands the Addressable Patient Pool
    • Growing Interest in Potassium Channelopathies Drives Research into Targeted Therapeutic Approaches for ATS
    • Here's the Story: Integration of Cardiac Monitoring and Neurological Assessment Enhances Holistic Management Strategies
    • Improved Access to Multidisciplinary Care Models Sustains Growth in Specialist Referral and Treatment Uptake
    • Rising Use of Off-Label Therapies and Symptom-Based Management Drives Demand for Personalized Care Plans
    • Global Expansion of Orphan Drug Programs Generates Opportunities for Novel ATS-Specific Therapeutics
    • Technological Innovation in Wearable ECG and Remote Monitoring Tools Supports Early Detection of Arrhythmic Events
    • Growing Focus on Pediatric Neurology and Genetic Counseling Strengthens Early Intervention Strategies for ATS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Andersen-Tawil Syndrome (ATS) Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Type 1 Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Type 1 Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Type 1 Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Type 2 Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Type 2 Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Type 2 Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION